nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—ABCB1—Methylprednisolone—ankylosing spondylitis	0.104	0.131	CbGbCtD
Loperamide—CYP2B6—Dexamethasone—ankylosing spondylitis	0.0771	0.0964	CbGbCtD
Loperamide—ABCB1—Betamethasone—ankylosing spondylitis	0.0679	0.085	CbGbCtD
Loperamide—ABCB1—Prednisolone—ankylosing spondylitis	0.067	0.0839	CbGbCtD
Loperamide—ABCB1—Prednisone—ankylosing spondylitis	0.0633	0.0792	CbGbCtD
Loperamide—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0626	0.0783	CbGbCtD
Loperamide—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0584	0.073	CbGbCtD
Loperamide—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0474	0.0594	CbGbCtD
Loperamide—CYP3A4—Betamethasone—ankylosing spondylitis	0.0407	0.0509	CbGbCtD
Loperamide—CYP3A4—Prednisolone—ankylosing spondylitis	0.0402	0.0502	CbGbCtD
Loperamide—ABCB1—Dexamethasone—ankylosing spondylitis	0.0395	0.0494	CbGbCtD
Loperamide—CYP3A4—Prednisone—ankylosing spondylitis	0.0379	0.0475	CbGbCtD
Loperamide—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0372	0.0466	CbGbCtD
Loperamide—ABCB1—Methotrexate—ankylosing spondylitis	0.0318	0.0397	CbGbCtD
Loperamide—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0237	0.0296	CbGbCtD
Loperamide—Megacolon toxic—Methotrexate—ankylosing spondylitis	0.0123	0.125	CcSEcCtD
Loperamide—CALM3—Uptake and function of anthrax toxins—ANTXR2—ankylosing spondylitis	0.0069	0.0673	CbGpPWpGaD
Loperamide—CALM1—Uptake and function of anthrax toxins—ANTXR2—ankylosing spondylitis	0.00668	0.0651	CbGpPWpGaD
Loperamide—CALM2—Uptake and function of anthrax toxins—ANTXR2—ankylosing spondylitis	0.00668	0.0651	CbGpPWpGaD
Loperamide—Megacolon—Methotrexate—ankylosing spondylitis	0.00625	0.0635	CcSEcCtD
Loperamide—Distention—Prednisone—ankylosing spondylitis	0.00521	0.0529	CcSEcCtD
Loperamide—CALM3—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.00453	0.0442	CbGpPWpGaD
Loperamide—CALM1—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.00438	0.0428	CbGpPWpGaD
Loperamide—CALM2—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.00438	0.0428	CbGpPWpGaD
Loperamide—CALM3—Uptake and actions of bacterial toxins—ANTXR2—ankylosing spondylitis	0.00437	0.0427	CbGpPWpGaD
Loperamide—CALM2—Uptake and actions of bacterial toxins—ANTXR2—ankylosing spondylitis	0.00423	0.0413	CbGpPWpGaD
Loperamide—CALM1—Uptake and actions of bacterial toxins—ANTXR2—ankylosing spondylitis	0.00423	0.0413	CbGpPWpGaD
Loperamide—POMC—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.00252	0.0246	CbGpPWpGaD
Loperamide—CACNA1A—Type II diabetes mellitus—TNF—ankylosing spondylitis	0.00222	0.0216	CbGpPWpGaD
Loperamide—POMC—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.00173	0.0169	CbGpPWpGaD
Loperamide—Dermatitis bullous—Prednisolone—ankylosing spondylitis	0.00128	0.013	CcSEcCtD
Loperamide—Anaphylactoid reaction—Prednisolone—ankylosing spondylitis	0.00127	0.0129	CcSEcCtD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.0012	0.0117	CbGpPWpGaD
Loperamide—Dermatitis bullous—Triamcinolone—ankylosing spondylitis	0.00118	0.012	CcSEcCtD
Loperamide—Anaphylactoid reaction—Triamcinolone—ankylosing spondylitis	0.00116	0.0118	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methylprednisolone—ankylosing spondylitis	0.00116	0.0118	CcSEcCtD
Loperamide—Dermatitis bullous—Dexamethasone—ankylosing spondylitis	0.00107	0.0109	CcSEcCtD
Loperamide—Dermatitis bullous—Betamethasone—ankylosing spondylitis	0.00107	0.0109	CcSEcCtD
Loperamide—Abdominal distension—Prednisolone—ankylosing spondylitis	0.00107	0.0108	CcSEcCtD
Loperamide—CALM3—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00106	0.0104	CbGpPWpGaD
Loperamide—Anaphylactoid reaction—Dexamethasone—ankylosing spondylitis	0.00106	0.0107	CcSEcCtD
Loperamide—Anaphylactoid reaction—Betamethasone—ankylosing spondylitis	0.00106	0.0107	CcSEcCtD
Loperamide—CALM1—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00103	0.01	CbGpPWpGaD
Loperamide—CALM2—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00103	0.01	CbGpPWpGaD
Loperamide—CALM1—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00102	0.00997	CbGpPWpGaD
Loperamide—CALM2—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00102	0.00997	CbGpPWpGaD
Loperamide—Depressed level of consciousness—Methotrexate—ankylosing spondylitis	0.00099	0.0101	CcSEcCtD
Loperamide—CALM3—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000983	0.00959	CbGpPWpGaD
Loperamide—Abdominal distension—Triamcinolone—ankylosing spondylitis	0.00098	0.00996	CcSEcCtD
Loperamide—Abdominal distension—Methylprednisolone—ankylosing spondylitis	0.000978	0.00994	CcSEcCtD
Loperamide—CALM1—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000951	0.00928	CbGpPWpGaD
Loperamide—CALM2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000951	0.00928	CbGpPWpGaD
Loperamide—OPRM1—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.000945	0.00921	CbGpPWpGaD
Loperamide—POMC—Metabolism of proteins—B3GNT2—ankylosing spondylitis	0.00094	0.00916	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000916	0.00894	CbGpPWpGaD
Loperamide—OPRM1—IL4-mediated signaling events—CD40LG—ankylosing spondylitis	0.000865	0.00844	CbGpPWpGaD
Loperamide—OPRM1—IL4-mediated signaling events—IL10—ankylosing spondylitis	0.000865	0.00844	CbGpPWpGaD
Loperamide—Abdominal distension—Prednisone—ankylosing spondylitis	0.000775	0.00787	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—ankylosing spondylitis	0.000769	0.00781	CcSEcCtD
Loperamide—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.000703	0.00714	CcSEcCtD
Loperamide—Angioedema—Prednisolone—ankylosing spondylitis	0.000674	0.00685	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.00067	0.00681	CcSEcCtD
Loperamide—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000649	0.00659	CcSEcCtD
Loperamide—OPRM1—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.000646	0.0063	CbGpPWpGaD
Loperamide—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000636	0.0062	CbGpPWpGaD
Loperamide—Discomfort—Prednisolone—ankylosing spondylitis	0.000621	0.00631	CcSEcCtD
Loperamide—Angioedema—Triamcinolone—ankylosing spondylitis	0.00062	0.0063	CcSEcCtD
Loperamide—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000619	0.00629	CcSEcCtD
Loperamide—CALM3—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000617	0.00602	CbGpPWpGaD
Loperamide—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000615	0.006	CbGpPWpGaD
Loperamide—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000615	0.006	CbGpPWpGaD
Loperamide—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000602	0.00612	CcSEcCtD
Loperamide—CALM1—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000597	0.00582	CbGpPWpGaD
Loperamide—CALM2—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000597	0.00582	CbGpPWpGaD
Loperamide—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000596	0.00606	CcSEcCtD
Loperamide—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000595	0.00605	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—ankylosing spondylitis	0.000573	0.00583	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000572	0.00582	CcSEcCtD
Loperamide—Discomfort—Triamcinolone—ankylosing spondylitis	0.000571	0.0058	CcSEcCtD
Loperamide—Discomfort—Methylprednisolone—ankylosing spondylitis	0.00057	0.00579	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000569	0.00578	CcSEcCtD
Loperamide—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000565	0.00574	CcSEcCtD
Loperamide—Angioedema—Dexamethasone—ankylosing spondylitis	0.000563	0.00572	CcSEcCtD
Loperamide—Angioedema—Betamethasone—ankylosing spondylitis	0.000563	0.00572	CcSEcCtD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000557	0.00543	CbGpPWpGaD
Loperamide—Immune system disorder—Prednisone—ankylosing spondylitis	0.000556	0.00565	CcSEcCtD
Loperamide—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000554	0.00563	CcSEcCtD
Loperamide—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000553	0.00562	CcSEcCtD
Loperamide—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000542	0.00551	CcSEcCtD
Loperamide—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000541	0.0055	CcSEcCtD
Loperamide—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000541	0.0055	CcSEcCtD
Loperamide—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000538	0.00524	CbGpPWpGaD
Loperamide—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000537	0.00546	CcSEcCtD
Loperamide—Discomfort—Betamethasone—ankylosing spondylitis	0.000518	0.00526	CcSEcCtD
Loperamide—Discomfort—Dexamethasone—ankylosing spondylitis	0.000518	0.00526	CcSEcCtD
Loperamide—POMC—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000518	0.00505	CbGpPWpGaD
Loperamide—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000508	0.00517	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000505	0.00513	CcSEcCtD
Loperamide—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000503	0.00511	CcSEcCtD
Loperamide—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000503	0.00511	CcSEcCtD
Loperamide—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000493	0.00501	CcSEcCtD
Loperamide—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000493	0.00501	CcSEcCtD
Loperamide—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000492	0.0048	CbGpPWpGaD
Loperamide—Angioedema—Prednisone—ankylosing spondylitis	0.00049	0.00498	CcSEcCtD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000489	0.00477	CbGpPWpGaD
Loperamide—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000487	0.00495	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000487	0.00495	CcSEcCtD
Loperamide—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000486	0.00494	CcSEcCtD
Loperamide—POMC—Metabolism—B3GNT2—ankylosing spondylitis	0.000484	0.00472	CbGpPWpGaD
Loperamide—Urticaria—Prednisolone—ankylosing spondylitis	0.000478	0.00486	CcSEcCtD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000477	0.00466	CbGpPWpGaD
Loperamide—Fatigue—Triamcinolone—ankylosing spondylitis	0.000477	0.00485	CcSEcCtD
Loperamide—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000476	0.00484	CcSEcCtD
Loperamide—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000471	0.00479	CcSEcCtD
Loperamide—POMC—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.00047	0.00459	CbGpPWpGaD
Loperamide—CALM3—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000467	0.00455	CbGpPWpGaD
Loperamide—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000465	0.00473	CcSEcCtD
Loperamide—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.000457	0.00446	CbGpPWpGaD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000453	0.00461	CcSEcCtD
Loperamide—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000452	0.00459	CcSEcCtD
Loperamide—CALM1—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000452	0.0044	CbGpPWpGaD
Loperamide—CALM2—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000452	0.0044	CbGpPWpGaD
Loperamide—Discomfort—Prednisone—ankylosing spondylitis	0.000451	0.00458	CcSEcCtD
Loperamide—CALM3—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000449	0.00438	CbGpPWpGaD
Loperamide—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000444	0.00451	CcSEcCtD
Loperamide—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000442	0.0045	CcSEcCtD
Loperamide—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000442	0.0045	CcSEcCtD
Loperamide—Urticaria—Triamcinolone—ankylosing spondylitis	0.00044	0.00447	CcSEcCtD
Loperamide—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000439	0.00446	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000438	0.00445	CcSEcCtD
Loperamide—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000437	0.00444	CcSEcCtD
Loperamide—CALM1—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000434	0.00423	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000434	0.00423	CbGpPWpGaD
Loperamide—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000434	0.00441	CcSEcCtD
Loperamide—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000434	0.00441	CcSEcCtD
Loperamide—Fatigue—Dexamethasone—ankylosing spondylitis	0.000433	0.0044	CcSEcCtD
Loperamide—Fatigue—Betamethasone—ankylosing spondylitis	0.000433	0.0044	CcSEcCtD
Loperamide—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000429	0.00436	CcSEcCtD
Loperamide—Skin disorder—Prednisone—ankylosing spondylitis	0.000425	0.00432	CcSEcCtD
Loperamide—CALM3—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000421	0.0041	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000419	0.00408	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—B3GNT2—ankylosing spondylitis	0.000419	0.00408	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000413	0.00403	CbGpPWpGaD
Loperamide—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000411	0.00418	CcSEcCtD
Loperamide—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000411	0.00418	CcSEcCtD
Loperamide—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000408	0.00415	CcSEcCtD
Loperamide—CALM1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000407	0.00397	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000407	0.00397	CbGpPWpGaD
Loperamide—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000407	0.00414	CcSEcCtD
Loperamide—Urticaria—Dexamethasone—ankylosing spondylitis	0.000399	0.00406	CcSEcCtD
Loperamide—Urticaria—Betamethasone—ankylosing spondylitis	0.000399	0.00406	CcSEcCtD
Loperamide—Dizziness—Prednisolone—ankylosing spondylitis	0.000398	0.00405	CcSEcCtD
Loperamide—Asthenia—Triamcinolone—ankylosing spondylitis	0.000397	0.00404	CcSEcCtD
Loperamide—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000397	0.00404	CcSEcCtD
Loperamide—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000397	0.00404	CcSEcCtD
Loperamide—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000396	0.00403	CcSEcCtD
Loperamide—Pruritus—Triamcinolone—ankylosing spondylitis	0.000392	0.00398	CcSEcCtD
Loperamide—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000391	0.00397	CcSEcCtD
Loperamide—Dyspepsia—Prednisone—ankylosing spondylitis	0.000385	0.00392	CcSEcCtD
Loperamide—Rash—Prednisolone—ankylosing spondylitis	0.00038	0.00386	CcSEcCtD
Loperamide—Dermatitis—Prednisolone—ankylosing spondylitis	0.000379	0.00386	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000379	0.00385	CcSEcCtD
Loperamide—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000378	0.00384	CcSEcCtD
Loperamide—Fatigue—Prednisone—ankylosing spondylitis	0.000377	0.00383	CcSEcCtD
Loperamide—Headache—Prednisolone—ankylosing spondylitis	0.000377	0.00383	CcSEcCtD
Loperamide—Discomfort—Methotrexate—ankylosing spondylitis	0.000377	0.00383	CcSEcCtD
Loperamide—Constipation—Prednisone—ankylosing spondylitis	0.000374	0.0038	CcSEcCtD
Loperamide—CALM3—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000372	0.00363	CbGpPWpGaD
Loperamide—CALM3—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000372	0.00362	CbGpPWpGaD
Loperamide—Dizziness—Triamcinolone—ankylosing spondylitis	0.000366	0.00372	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000366	0.00372	CcSEcCtD
Loperamide—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000365	0.00371	CcSEcCtD
Loperamide—OPRD1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000364	0.00355	CbGpPWpGaD
Loperamide—Asthenia—Betamethasone—ankylosing spondylitis	0.000361	0.00366	CcSEcCtD
Loperamide—Asthenia—Dexamethasone—ankylosing spondylitis	0.000361	0.00366	CcSEcCtD
Loperamide—CALM2—DAP12 interactions—HLA-C—ankylosing spondylitis	0.00036	0.00351	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—HLA-C—ankylosing spondylitis	0.00036	0.00351	CbGpPWpGaD
Loperamide—CALM2—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000359	0.00351	CbGpPWpGaD
Loperamide—CALM1—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000359	0.00351	CbGpPWpGaD
Loperamide—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000359	0.00365	CcSEcCtD
Loperamide—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000358	0.00364	CcSEcCtD
Loperamide—Nausea—Prednisolone—ankylosing spondylitis	0.000358	0.00364	CcSEcCtD
Loperamide—Pruritus—Dexamethasone—ankylosing spondylitis	0.000356	0.00361	CcSEcCtD
Loperamide—Pruritus—Betamethasone—ankylosing spondylitis	0.000356	0.00361	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—ankylosing spondylitis	0.000355	0.00361	CcSEcCtD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000354	0.00345	CbGpPWpGaD
Loperamide—Vomiting—Triamcinolone—ankylosing spondylitis	0.000352	0.00358	CcSEcCtD
Loperamide—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000351	0.00357	CcSEcCtD
Loperamide—Rash—Triamcinolone—ankylosing spondylitis	0.000349	0.00355	CcSEcCtD
Loperamide—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000349	0.00355	CcSEcCtD
Loperamide—Rash—Methylprednisolone—ankylosing spondylitis	0.000348	0.00354	CcSEcCtD
Loperamide—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000348	0.00354	CcSEcCtD
Loperamide—Urticaria—Prednisone—ankylosing spondylitis	0.000348	0.00353	CcSEcCtD
Loperamide—Headache—Triamcinolone—ankylosing spondylitis	0.000347	0.00353	CcSEcCtD
Loperamide—Headache—Methylprednisolone—ankylosing spondylitis	0.000346	0.00352	CcSEcCtD
Loperamide—Abdominal pain—Prednisone—ankylosing spondylitis	0.000346	0.00352	CcSEcCtD
Loperamide—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000344	0.00349	CcSEcCtD
Loperamide—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000344	0.00349	CcSEcCtD
Loperamide—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000336	0.00328	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000335	0.00326	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000334	0.00326	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000334	0.00326	CbGpPWpGaD
Loperamide—Dizziness—Dexamethasone—ankylosing spondylitis	0.000332	0.00338	CcSEcCtD
Loperamide—Dizziness—Betamethasone—ankylosing spondylitis	0.000332	0.00338	CcSEcCtD
Loperamide—Nausea—Triamcinolone—ankylosing spondylitis	0.000329	0.00334	CcSEcCtD
Loperamide—Nausea—Methylprednisolone—ankylosing spondylitis	0.000328	0.00334	CcSEcCtD
Loperamide—Somnolence—Methotrexate—ankylosing spondylitis	0.000325	0.0033	CcSEcCtD
Loperamide—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000322	0.00328	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000322	0.00327	CcSEcCtD
Loperamide—Vomiting—Dexamethasone—ankylosing spondylitis	0.000319	0.00325	CcSEcCtD
Loperamide—Vomiting—Betamethasone—ankylosing spondylitis	0.000319	0.00325	CcSEcCtD
Loperamide—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000319	0.00311	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000319	0.00311	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000318	0.0031	CbGpPWpGaD
Loperamide—Rash—Dexamethasone—ankylosing spondylitis	0.000317	0.00322	CcSEcCtD
Loperamide—Rash—Betamethasone—ankylosing spondylitis	0.000317	0.00322	CcSEcCtD
Loperamide—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000317	0.00322	CcSEcCtD
Loperamide—Dermatitis—Betamethasone—ankylosing spondylitis	0.000317	0.00322	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000316	0.00321	CcSEcCtD
Loperamide—Fatigue—Methotrexate—ankylosing spondylitis	0.000315	0.0032	CcSEcCtD
Loperamide—Headache—Dexamethasone—ankylosing spondylitis	0.000315	0.0032	CcSEcCtD
Loperamide—Headache—Betamethasone—ankylosing spondylitis	0.000315	0.0032	CcSEcCtD
Loperamide—Asthenia—Prednisone—ankylosing spondylitis	0.000314	0.00319	CcSEcCtD
Loperamide—Pruritus—Prednisone—ankylosing spondylitis	0.00031	0.00315	CcSEcCtD
Loperamide—Diarrhoea—Prednisone—ankylosing spondylitis	0.000299	0.00304	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000299	0.00304	CcSEcCtD
Loperamide—Nausea—Betamethasone—ankylosing spondylitis	0.000298	0.00303	CcSEcCtD
Loperamide—Nausea—Dexamethasone—ankylosing spondylitis	0.000298	0.00303	CcSEcCtD
Loperamide—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000295	0.00287	CbGpPWpGaD
Loperamide—Urticaria—Methotrexate—ankylosing spondylitis	0.000291	0.00295	CcSEcCtD
Loperamide—Dizziness—Prednisone—ankylosing spondylitis	0.000289	0.00294	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000289	0.00294	CcSEcCtD
Loperamide—Vomiting—Prednisone—ankylosing spondylitis	0.000278	0.00283	CcSEcCtD
Loperamide—POMC—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000278	0.00271	CbGpPWpGaD
Loperamide—Rash—Prednisone—ankylosing spondylitis	0.000276	0.0028	CcSEcCtD
Loperamide—Dermatitis—Prednisone—ankylosing spondylitis	0.000276	0.0028	CcSEcCtD
Loperamide—Headache—Prednisone—ankylosing spondylitis	0.000274	0.00279	CcSEcCtD
Loperamide—OPRM1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000269	0.00263	CbGpPWpGaD
Loperamide—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000269	0.00274	CcSEcCtD
Loperamide—CALM3—B Cell Activation—CD79A—ankylosing spondylitis	0.000263	0.00256	CbGpPWpGaD
Loperamide—Asthenia—Methotrexate—ankylosing spondylitis	0.000262	0.00267	CcSEcCtD
Loperamide—Nausea—Prednisone—ankylosing spondylitis	0.00026	0.00264	CcSEcCtD
Loperamide—Pruritus—Methotrexate—ankylosing spondylitis	0.000259	0.00263	CcSEcCtD
Loperamide—CALM3—Immune System—KIR3DL1—ankylosing spondylitis	0.000255	0.00249	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—CD79A—ankylosing spondylitis	0.000254	0.00248	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—CD79A—ankylosing spondylitis	0.000254	0.00248	CbGpPWpGaD
Loperamide—Diarrhoea—Methotrexate—ankylosing spondylitis	0.00025	0.00254	CcSEcCtD
Loperamide—CALM1—Immune System—KIR3DL1—ankylosing spondylitis	0.000247	0.00241	CbGpPWpGaD
Loperamide—CALM2—Immune System—KIR3DL1—ankylosing spondylitis	0.000247	0.00241	CbGpPWpGaD
Loperamide—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000242	0.00236	CbGpPWpGaD
Loperamide—Dizziness—Methotrexate—ankylosing spondylitis	0.000242	0.00246	CcSEcCtD
Loperamide—CALM3—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000242	0.00236	CbGpPWpGaD
Loperamide—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000234	0.00228	CbGpPWpGaD
Loperamide—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000234	0.00228	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000234	0.00228	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000234	0.00228	CbGpPWpGaD
Loperamide—Vomiting—Methotrexate—ankylosing spondylitis	0.000233	0.00236	CcSEcCtD
Loperamide—Rash—Methotrexate—ankylosing spondylitis	0.000231	0.00234	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—ankylosing spondylitis	0.00023	0.00234	CcSEcCtD
Loperamide—CALM3—Innate Immune System—CARD9—ankylosing spondylitis	0.00023	0.00225	CbGpPWpGaD
Loperamide—Headache—Methotrexate—ankylosing spondylitis	0.000229	0.00233	CcSEcCtD
Loperamide—CALM2—Innate Immune System—CARD9—ankylosing spondylitis	0.000223	0.00217	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CARD9—ankylosing spondylitis	0.000223	0.00217	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—HLA-B—ankylosing spondylitis	0.00022	0.00215	CbGpPWpGaD
Loperamide—Nausea—Methotrexate—ankylosing spondylitis	0.000217	0.00221	CcSEcCtD
Loperamide—CALM2—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000217	0.00212	CbGpPWpGaD
Loperamide—CALM1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000217	0.00212	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000213	0.00208	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000213	0.00208	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000205	0.002	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—MMP3—ankylosing spondylitis	0.000198	0.00193	CbGpPWpGaD
Loperamide—CALM3—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000194	0.00189	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000188	0.00183	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000188	0.00183	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000187	0.00182	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.00018	0.00176	CbGpPWpGaD
Loperamide—CALM3—Disease—ANTXR2—ankylosing spondylitis	0.000179	0.00174	CbGpPWpGaD
Loperamide—CALM2—Disease—ANTXR2—ankylosing spondylitis	0.000173	0.00169	CbGpPWpGaD
Loperamide—CALM1—Disease—ANTXR2—ankylosing spondylitis	0.000173	0.00169	CbGpPWpGaD
Loperamide—CALM3—Alzheimers Disease—TNF—ankylosing spondylitis	0.000168	0.00164	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000164	0.0016	CbGpPWpGaD
Loperamide—CALM2—Alzheimers Disease—TNF—ankylosing spondylitis	0.000162	0.00158	CbGpPWpGaD
Loperamide—CALM1—Alzheimers Disease—TNF—ankylosing spondylitis	0.000162	0.00158	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1R2—ankylosing spondylitis	0.000155	0.00151	CbGpPWpGaD
Loperamide—CALM2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000155	0.00151	CbGpPWpGaD
Loperamide—CALM1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000155	0.00151	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000152	0.00149	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1R2—ankylosing spondylitis	0.00015	0.00146	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1R2—ankylosing spondylitis	0.00015	0.00146	CbGpPWpGaD
Loperamide—CALM3—Immune System—ERAP1—ankylosing spondylitis	0.000147	0.00143	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HLA-C—ankylosing spondylitis	0.000145	0.00141	CbGpPWpGaD
Loperamide—CALM2—Immune System—ERAP1—ankylosing spondylitis	0.000142	0.00138	CbGpPWpGaD
Loperamide—CALM1—Immune System—ERAP1—ankylosing spondylitis	0.000142	0.00138	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HLA-C—ankylosing spondylitis	0.00014	0.00136	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HLA-C—ankylosing spondylitis	0.00014	0.00136	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000139	0.00135	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000138	0.00135	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000134	0.00131	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000134	0.00131	CbGpPWpGaD
Loperamide—CALM3—Immune System—CARD9—ankylosing spondylitis	0.000134	0.00131	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000133	0.0013	CbGpPWpGaD
Loperamide—CALM2—Immune System—CARD9—ankylosing spondylitis	0.00013	0.00127	CbGpPWpGaD
Loperamide—CALM1—Immune System—CARD9—ankylosing spondylitis	0.00013	0.00127	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	0.000127	0.00124	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000116	0.00114	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.00011	0.00107	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000106	0.00103	CbGpPWpGaD
Loperamide—CALM3—Disease—B3GNT2—ankylosing spondylitis	0.000105	0.00103	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000102	0.000999	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000102	0.000999	CbGpPWpGaD
Loperamide—CALM2—Disease—B3GNT2—ankylosing spondylitis	0.000102	0.000993	CbGpPWpGaD
Loperamide—CALM1—Disease—B3GNT2—ankylosing spondylitis	0.000102	0.000993	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—MMP3—ankylosing spondylitis	9.85e-05	0.00096	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PTGER4—ankylosing spondylitis	9.67e-05	0.000943	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—B3GNT2—ankylosing spondylitis	9.06e-05	0.000883	CbGpPWpGaD
Loperamide—CALM3—Metabolism—B3GNT2—ankylosing spondylitis	8.82e-05	0.00086	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.63e-05	0.000842	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.56e-05	0.000835	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HLA-B—ankylosing spondylitis	8.55e-05	0.000834	CbGpPWpGaD
Loperamide—CALM2—Metabolism—B3GNT2—ankylosing spondylitis	8.53e-05	0.000832	CbGpPWpGaD
Loperamide—CALM1—Metabolism—B3GNT2—ankylosing spondylitis	8.53e-05	0.000832	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-C—ankylosing spondylitis	8.42e-05	0.000821	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.35e-05	0.000814	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.35e-05	0.000814	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.28e-05	0.000808	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.28e-05	0.000808	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HLA-B—ankylosing spondylitis	8.27e-05	0.000807	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HLA-B—ankylosing spondylitis	8.27e-05	0.000807	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-B—ankylosing spondylitis	8.21e-05	0.000801	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PTGER4—ankylosing spondylitis	8.17e-05	0.000797	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-C—ankylosing spondylitis	8.15e-05	0.000794	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-C—ankylosing spondylitis	8.15e-05	0.000794	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.94e-05	0.000775	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.94e-05	0.000775	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MMP3—ankylosing spondylitis	7.85e-05	0.000765	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	7.67e-05	0.000748	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.61e-05	0.000742	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—CRP—ankylosing spondylitis	7.56e-05	0.000737	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.36e-05	0.000718	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.36e-05	0.000718	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1RN—ankylosing spondylitis	7.32e-05	0.000713	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CRP—ankylosing spondylitis	7.31e-05	0.000713	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—CRP—ankylosing spondylitis	7.31e-05	0.000713	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—TLR4—ankylosing spondylitis	7.25e-05	0.000707	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1RN—ankylosing spondylitis	7.08e-05	0.00069	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1RN—ankylosing spondylitis	7.08e-05	0.00069	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—TLR4—ankylosing spondylitis	7.01e-05	0.000684	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—TLR4—ankylosing spondylitis	7.01e-05	0.000684	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MMP3—ankylosing spondylitis	6.88e-05	0.000671	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	6.68e-05	0.000652	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD79A—ankylosing spondylitis	6.42e-05	0.000626	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	6.3e-05	0.000614	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	6.28e-05	0.000612	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD79A—ankylosing spondylitis	6.21e-05	0.000606	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD79A—ankylosing spondylitis	6.21e-05	0.000606	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—MMP3—ankylosing spondylitis	6.09e-05	0.000594	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—MMP3—ankylosing spondylitis	5.9e-05	0.000575	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—MMP3—ankylosing spondylitis	5.9e-05	0.000575	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP3—ankylosing spondylitis	5.82e-05	0.000567	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1A—ankylosing spondylitis	5.27e-05	0.000514	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD40LG—ankylosing spondylitis	5.24e-05	0.000511	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1A—ankylosing spondylitis	5.09e-05	0.000497	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1A—ankylosing spondylitis	5.09e-05	0.000497	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD40LG—ankylosing spondylitis	5.06e-05	0.000494	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD40LG—ankylosing spondylitis	5.06e-05	0.000494	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTGER4—ankylosing spondylitis	5.06e-05	0.000493	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-B—ankylosing spondylitis	4.98e-05	0.000486	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTGER4—ankylosing spondylitis	4.89e-05	0.000477	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTGER4—ankylosing spondylitis	4.89e-05	0.000477	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-B—ankylosing spondylitis	4.82e-05	0.00047	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-B—ankylosing spondylitis	4.82e-05	0.00047	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-A—ankylosing spondylitis	4.61e-05	0.00045	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-A—ankylosing spondylitis	4.46e-05	0.000435	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-A—ankylosing spondylitis	4.46e-05	0.000435	CbGpPWpGaD
Loperamide—CALM3—Immune System—CRP—ankylosing spondylitis	4.4e-05	0.000429	CbGpPWpGaD
Loperamide—CALM3—Disease—HLA-A—ankylosing spondylitis	4.26e-05	0.000415	CbGpPWpGaD
Loperamide—CALM1—Immune System—CRP—ankylosing spondylitis	4.26e-05	0.000415	CbGpPWpGaD
Loperamide—CALM2—Immune System—CRP—ankylosing spondylitis	4.26e-05	0.000415	CbGpPWpGaD
Loperamide—CALM3—Immune System—TLR4—ankylosing spondylitis	4.22e-05	0.000412	CbGpPWpGaD
Loperamide—CALM2—Disease—HLA-A—ankylosing spondylitis	4.12e-05	0.000402	CbGpPWpGaD
Loperamide—CALM1—Disease—HLA-A—ankylosing spondylitis	4.12e-05	0.000402	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	4.12e-05	0.000401	CbGpPWpGaD
Loperamide—CALM1—Immune System—TLR4—ankylosing spondylitis	4.08e-05	0.000398	CbGpPWpGaD
Loperamide—CALM2—Immune System—TLR4—ankylosing spondylitis	4.08e-05	0.000398	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP3—ankylosing spondylitis	3.6e-05	0.000351	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP3—ankylosing spondylitis	3.48e-05	0.00034	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP3—ankylosing spondylitis	3.48e-05	0.00034	CbGpPWpGaD
